4//SEC Filing
Eisele Jeffrey 4
Accession 0001127602-24-002738
CIK 0001492422other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 4:23 PM ET
Size
6.1 KB
Accession
0001127602-24-002738
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2024-01-30$65.53/sh−971$63,630→ 57,208 total - Sale
Common Stock
2024-01-29$64.14/sh−279$17,895→ 58,179 total
Footnotes (2)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/26/2024.
- [F2]This is a scheduled sale from an established 10b5-1 plan.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001827326
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 4:23 PM ET
- Size
- 6.1 KB